The Swiss competition commission (COMCO) has opened an investigation into suspected unlawful use of a patent to reduce competitive pressure by Swiss pharmaceutical giant Novartis.
This content was published on
1 minute
Keystone-SDA/reuters/jdp
Español
es
Investigan a Novartis por sospecha de abuso de patentes
The probe, which is in collaboration with the European Commission, is looking into whether the company used unlawful means to ward off competition for its own dermatological treatments. COMCO conducted an early morning raid at the company’s Basel headquarters on September 13 in connection with the probe.
“The company allegedly attempted to protect its drug for the treatment of skin diseases against competing products by using one of its patents to initiate litigation proceedings,” COMCO said in a statementExternal link, which didn’t mention the company by name.
The investigation seeks to determine whether the alleged behaviour constitutes the use of a so-called blocking patent, which might amount to an unlawful abuse of an allegedly dominant position according to the Swiss Cartel Act.
In a press releaseExternal link, Novartis confirmed authorities had “visited” the company and said the “opening of an investigation does not imply any finding of wrongdoing or any financial impact. Novartis is fully cooperating with the authorities and is confident to clarify the legitimacy of its position”.
The company told the financial news site AWP that the search was limited to the Basel headquarters.
Popular Stories
More
Banking & Fintech
UBS releases ‘hundreds’ of staff in fresh wave of job cuts
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
This content was published on
A committee of Switzerland’s House of Representatives has found the people’s initiative to limit fireworks too extreme, but has suggested a counter-proposal.
UN investigators report evidence of crimes in Syria and call for national dialogue
This content was published on
UN investigators in Geneva report ample evidence of crimes in Syria and urge the regime to follow through on its promise of a national dialogue.
Swiss Trade Union warns EU deal could threaten wages
This content was published on
The Swiss Trade Union Federation warns that the new bilateral agreement between Switzerland and the EU could threaten wage protection and public services.
Credit Suisse fines from Mozambique scandal to fund victims’ compensation
This content was published on
The fines imposed on Credit Suisse for the Mozambique scandal will be allocated to a fund for the victims, amounting to $105.5 million.
‘Confederation is a subsidy machine’: Swiss finance minister
This content was published on
The Swiss government is a machine for distributing subsidies to various actors in the country, says finance minister Karin Keller-Sutter.
Lack of funds ends third bid to salvage Säntis ship from Swiss lake
This content was published on
A third attempt to salvage the steamship Säntis, lying at the bottom of Lake Constance in Switzerland since 1933, has failed before it has even begun.
Nestlé Waters on trial in France over illegal waste dumps
This content was published on
Bottled water producer Nestlé Waters to stand trial, accused of illegally dumping waste and maintaining unauthorised dumps.
This content was published on
Costs for the health sector, gas and digital payment transactions all ended up in the cross hairs of the Swiss price supervisor last year.
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.